These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2242545)

  • 1. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias.
    Colatsky TJ; Follmer CH; Starmer CF
    Circulation; 1990 Dec; 82(6):2235-42. PubMed ID: 2242545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the mechanism of action of antiarrhythmic agents.
    Grant AO
    Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
    Hondeghem LM; Carlsson L; Duker G
    Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.
    McCauley M; Vallabhajosyula S; Darbar D
    Card Electrophysiol Clin; 2016 Jun; 8(2):481-93. PubMed ID: 27261836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential.
    Nair LA; Grant AO
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular and ionic specificity of antiarrhythmic drug actions.
    Nattel S
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):272-82. PubMed ID: 10090234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of the use-dependent sodium channel block and reverse use-dependent potassium channel block of class I and class III antiarrhythmic agents and their values to predict drug efficacy].
    Sadanaga T; Ogawa S; Okada Y; Handa S
    Jpn Circ J; 1992; 56 Suppl 5():1474-6. PubMed ID: 1337923
    [No Abstract]   [Full Text] [Related]  

  • 10. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.
    Roden DM
    Eur Heart J; 1993 Nov; 14 Suppl H():56-61. PubMed ID: 8293755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of the IKs channel complex inhibits drug block: novel mechanism underlying variable antiarrhythmic drug actions.
    Yang T; Kanki H; Roden DM
    Circulation; 2003 Jul; 108(2):132-4. PubMed ID: 12835205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
    Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
    J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic interactions between pinacidil, a potassium channel opener and class I antiarrhythmic agents in guinea-pig isolated perfused heart.
    Yang Q; Padrini R; Bova S; Piovan D; Magnolfi G
    Br J Pharmacol; 1995 Apr; 114(8):1745-9. PubMed ID: 7599944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
    Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia.
    Schmitt N; Grunnet M; Olesen SP
    Physiol Rev; 2014 Apr; 94(2):609-53. PubMed ID: 24692356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of antiarrhythmic drugs.
    Capucci A; Aschieri D; Villani GQ
    Drugs Aging; 1998 Jul; 13(1):51-70. PubMed ID: 9679209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.